NASDAQ: RDNTRadnet Inc Stock
$64.95+1.22 (+1.91%)
Updated Jan 23, 2025
RDNT Price
$64.95
Fair Value Price
-$17.24
Market Cap
$4.81B
52 Week Low
$35.16
52 Week High
$93.65
P/E
-927.86x
P/B
5.37x
P/S
2.88x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.77B
Earnings
-$4.41M
Gross Margin
13.9%
Operating Margin
4.49%
Profit Margin
-0.2%
Debt to Equity
2.41
Operating Cash Flow
$279M
Beta
1.37
Next Earnings
Feb 26, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RDNT Overview
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RDNT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
B
Growth
C
Momentum
F
Sentiment
C
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important RDNT news, forecast changes, insider trades & much more!
RDNT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RDNT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RDNT ($64.95) is overvalued by 476.64% relative to our estimate of its Fair Value price of -$17.24 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RDNT ($64.95) is not significantly undervalued (476.64%) relative to our estimate of its Fair Value price of -$17.24 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RDNT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RDNT due diligence checks available for Premium users.
Valuation
RDNT fair value
Fair Value of RDNT stock based on Discounted Cash Flow (DCF)
Price
$64.95
Fair Value
-$17.24
Undervalued by
476.64%
RDNT ($64.95) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RDNT ($64.95) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RDNT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RDNT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-927.86x
Industry
25.39x
Market
30.03x
RDNT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.37x
Industry
4.23x
RDNT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RDNT's financial health
Profit margin
Revenue
$461.1M
Net Income
$3.2M
Profit Margin
0.7%
RDNT's Earnings (EBIT) of $79.63M... subscribe to Premium to read more.
Interest Coverage Financials
RDNT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.3B
Liabilities
$2.2B
Debt to equity
2.41
RDNT's short-term assets ($1.02B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RDNT's long-term liabilities ($1.69B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RDNT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RDNT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$57.4M
Investing
-$46.0M
Financing
-$4.3M
RDNT's operating cash flow ($279.41M)... subscribe to Premium to read more.
Debt Coverage Financials
RDNT vs Diagnostic & Research Stocks
Radnet Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.